Lv21
156 积分 2021-04-20 加入
An agentic system for rare disease diagnosis with traceable reasoning
1个月前
已完结
Deep-learning-based HER2 status assessment from multimodal breast cancer data predicts neoadjuvant therapy response
3个月前
已完结
Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab
4个月前
已完结
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab
4个月前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
8个月前
已完结
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
8个月前
已完结
Silent mutations make noise
9个月前
已完结
皖公网安备34019202002308
